Acquisition of HCMV from breast milk-correlates of protection

从母乳中获得 HCMV——保护的相关性

• 批准号: 9122090
• 负责人: Suresh B Boppana
• 金额: $ 71.24万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-05 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9122090
• 关键词: AIDS/HIV problem; Allografting; Animals; Antibodies; Antibody Response; Antigens; Antiviral Agents; Appearance; Breast; Characteristics; Clinical Data; Clinical Trials; Cytomegalovirus; Cytomegalovirus Infections; Empiricism; Epithelial; Exposure to; Future; Genome; Glycoproteins; Goals; Health; High-Throughput Nucleotide Sequencing; Human; Human Milk; Immune; Immune response; Immunity; Immunocompromised Host; Immunoglobulin A; Immunoglobulin G; Immunologics; Infant; Infection; Lead; Life; Liquid substance; Minor; Modeling; Morbidity - disease rate; Mothers; Mucous Membrane; Mutation; Neurologic; Observational Study; Oral mucous membrane structure; Pattern; Population; Prevention; Role; Saliva; Secondary to; Sensorineural Hearing Loss; Specificity; Specimen; Surface; Testing; Vaccines; Variant; Viral; Viral Antibodies; Viral Genome; Viral Load result; Viral Proteins; Virus; Virus Diseases; Virus Replication; adaptive immunity; antiviral immunity; congenital infection; design; env Gene Products; in vivo Model; neutralizing antibody; non-genetic; pressure; prevent; recombinant virus; response; seropositive; success; transmission process; vaccine development; vaccine trial; viral transmission

DESCRIPTION (provided by applicant): Congenital human cytomegalovirus (HCMV) infection is the most common viral infection a leading non- genetic cause of sensorineural hearing loss and other neurological sequelae. Although prevention of this intrauterine infection remains a high priority for vaccine development, currently no vaccine is available and early clinical trials have had only limited success. Understanding the role of antiviral antibody responses in limiting virus transmission is a necessary prerequisite for the successful design of an efficacious vaccine. Since the characteristics of antiviral immune responses that limit HCMV acquisition are unknown, identification of potentially protective responses in the normal host will continue to rel on the empiricism vaccine trials with candidate immunogens selected by a combination of good faith and limited data from clinical observations and studies in experimental animals. Infants born to seropositive mothers are passively immunized by antiviral antibodies acquired transplacentally and via breast milk including neutralizing antibodies, yet, are consistently infected following epithelial exposure to virus present within breast milk. Although these findings might argue that HCMV immunity offers little protection against virus acquisition, since only about half of the infants exposed to HCMV in breast milk will become infected, this model of natural HCMV acquisition provides an unique opportunity to define virologic and immunologic correlates of protection from acquisition of HCMV. By investigating the breast milk transmission of HCMV, we expect to develop a better understanding of the protective antiviral immune responses against mucosal acquisition of HCMV. It is our hypothesis that acquisition of HCMV following exposure of the infant's oral mucosa to HCMV-infected breast milk occurs when inadequate immune control of viral replication or emergence of new viral genome types overcoming the virus-host protective threshold required to prevent transmission. Delineation of the mechanisms leading to this breech of protective antiviral immunity will lead to a more rational design of immunogens capable of inducing protective immunity to HCMV. The goals of the project are to determine the quantity, specificity, and function of HCMV-specific antibodies in maternal breast milk and infant saliva, and the HCMV genome variability patterns associated with lower viral load and antiviral antibodies in these fluids and protection from HCMV breast milk transmission over the first 6 months after delivery.

描述（由申请人提供）：先天性人类巨细胞病毒（HCMV）感染是最常见的病毒感染，是引起感音神经性听力损失和其他神经系统后遗症的主要非遗传原因。尽管预防这种宫内感染仍然是疫苗开发的高度优先事项，但目前还没有疫苗可用，早期临床试验也只取得了有限的成功。了解抗病毒抗体反应在限制病毒传播中的作用是成功设计有效疫苗的必要前提。由于限制HCMV获得的抗病毒免疫反应的特征尚不清楚，在正常宿主中识别潜在的保护性反应将继续依赖于经验主义疫苗试验，候选免疫原是通过诚信和有限的临床观察数据和实验动物研究选择的。血清阳性母亲所生的婴儿通过经胎盘和母乳获得的抗病毒抗体（包括中和抗体）被动免疫，然而，在上皮细胞暴露于母乳中存在的病毒后，婴儿始终受到感染。尽管这些发现